Abstract | PURPOSE: MATERIALS AND METHODS:
Tumor specimens from 272 consecutive patients treated with RC for advanced BC were assessed with immunohistochemical staining for uPA, uPAR, and PAI-1. Overexpression was assessed by pathological image analysis. Kaplan-Meier estimates and multivariable Cox-regression were used to analyze survival. Harrell's C-index was used to assess for clinical impact of the uPA system. RESULTS: uPA, uPAR, and PAI-1 were overexpressed in 48.2%, 51.1%, and 52.2% of patients, respectively. uPA overexpression was associated with lymphovascular invasion (P = 0.034) and nodal status (P = 0.013); PAI-1 overexpression was associated with primary muscle-invasive BC (P = 0.015) and lymphovascular invasion (P = 0.024). uPA, uPAR, and the number of overexpressed markers were all 3 significantly associated with shorter overall recurrence-free-, distant recurrence-free-, and cancer-specific survival. In multivariable analyses, uPA overexpression remained associated with shorter recurrence-free survival (hazard ratio [HR] = 1.79; P = 0.036) in the entire cohort, in patients without lymph node metastasis (HR = 1.98; P = 0.018) and those with nonorgan-confined disease (HR = 1.98; P = 0.022). uPAR overexpression was associated with shorter recurrence-free survival in patients without lymph node metastasis (HR = 2.01; P = 0.021) and those with organ-confined disease (HR = 4.11; P = 0.037). CONCLUSION: Members of the uPA system are associated with features of biologically aggressive BC and oncologic outcomes. However, their value beyond currently available information remains limited.
|
Authors | Florian Janisch, David D'Andrea, Takehiro Iwata, Shoji Kimura, Mohammad Abufaraj, Dmitry Enikeev, Petr V Glybochko, Pierre I Karakiewicz, Peter Nyirady, Harun Fajkovic, Andrea Haitel, Veronika Seebacher, Michael Rink, Shahrokh F Shariat |
Journal | Urologic oncology
(Urol Oncol)
Vol. 38
Issue 5
Pg. 423-432
(05 2020)
ISSN: 1873-2496 [Electronic] United States |
PMID | 32209281
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier Inc. All rights reserved. |
Chemical References |
- PLAUR protein, human
- Plasminogen Activator Inhibitor 1
- Receptors, Urokinase Plasminogen Activator
- Urokinase-Type Plasminogen Activator
|
Topics |
- Aged
- Cohort Studies
- Cystectomy
(methods)
- Female
- Humans
- Male
- Middle Aged
- Plasminogen Activator Inhibitor 1
(analysis, physiology)
- Prognosis
- Receptors, Urokinase Plasminogen Activator
(analysis, physiology)
- Retrospective Studies
- Survival Rate
- Urinary Bladder Neoplasms
(chemistry, mortality, surgery)
- Urokinase-Type Plasminogen Activator
(analysis, physiology)
|